Empirical meropenem versus piperacillin/tazobactam for adult patients with sepsis (EMPRESS) trial: Protocol.

Anders Granholm Marie Warrer Munch Nick Meier Fredrik SjövallMarie HellebergFrederik Boetius Hertz Benjamin Skov Kaas-HansenHans-Christian Thorsen-MeyerLars Wiuff Andersen Bodil Steen RasmussenJakob Steen AndersenTrine Lynge AlbertsenMaj-Brit Nørerregaard KjaerAksel Karl Georg JensenTheis LangeAnders PernerMorten Hylander Møller

Published in: Acta anaesthesiologica Scandinavica (2024)

EMPRESS will compare the effects of empirical meropenem against piperacillin/tazobactam in adult, critically ill patients with sepsis. Due to the pragmatic, adaptive design with high probability of conclusiveness, the trial results are expected to directly inform clinical practice.

Keyphrases

gram negative
study protocol
clinical practice
phase iii
septic shock
acute kidney injury
randomized controlled trial
intensive care unit
phase ii
clinical trial
multidrug resistant
open label